AIxCrypto Holdings, Inc.

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, ONC has a market cap of 33.2B. Regarding current trading prices, AIXC is priced at $1.28, while ONC trades at $310.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas ONC's P/E ratio is 125.83. In terms of profitability, AIXC's ROE is -1.05%, compared to ONC's ROE of +0.07%. Regarding short-term risk, AIXC is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ONC's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, AIXC is priced at $1.28, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas WBA's P/E ratio is -1.64. In terms of profitability, AIXC's ROE is -1.05%, compared to WBA's ROE of -0.39%. Regarding short-term risk, AIXC is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check WBA's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, DMRA has a market cap of 1.5B. Regarding current trading prices, AIXC is priced at $1.28, while DMRA trades at $25.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas DMRA's P/E ratio is -6.30. In terms of profitability, AIXC's ROE is -1.05%, compared to DMRA's ROE of -1.47%. Regarding short-term risk, AIXC is less volatile compared to DMRA. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check DMRA's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, AIXC is priced at $1.28, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas HROWL's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to HROWL's ROE of -0.10%. Regarding short-term risk, AIXC is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HROWL's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, AIXC is priced at $1.28, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas HROWM's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to HROWM's ROE of -0.10%. Regarding short-term risk, AIXC is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HROWM's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFMDP has a market cap of 1B. Regarding current trading prices, AIXC is priced at $1.28, while LFMDP trades at $23.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas LFMDP's P/E ratio is -10.22. In terms of profitability, AIXC's ROE is -1.05%, compared to LFMDP's ROE of -1.18%. Regarding short-term risk, AIXC is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFMDP's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, CGEM has a market cap of 873.4M. Regarding current trading prices, AIXC is priced at $1.28, while CGEM trades at $14.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas CGEM's P/E ratio is -4.29. In terms of profitability, AIXC's ROE is -1.05%, compared to CGEM's ROE of -0.46%. Regarding short-term risk, AIXC is less volatile compared to CGEM. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check CGEM's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, ATAI has a market cap of 714.9M. Regarding current trading prices, AIXC is priced at $1.28, while ATAI trades at $3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas ATAI's P/E ratio is -4.57. In terms of profitability, AIXC's ROE is -1.05%, compared to ATAI's ROE of -3.90%. Regarding short-term risk, AIXC is less volatile compared to ATAI. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check ATAI's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, HITI has a market cap of 203M. Regarding current trading prices, AIXC is priced at $1.28, while HITI trades at $2.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas HITI's P/E ratio is -5.50. In terms of profitability, AIXC's ROE is -1.05%, compared to HITI's ROE of -0.41%. Regarding short-term risk, AIXC is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HITI's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFMD has a market cap of 168.4M. Regarding current trading prices, AIXC is priced at $1.28, while LFMD trades at $3.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas LFMD's P/E ratio is -11.70. In terms of profitability, AIXC's ROE is -1.05%, compared to LFMD's ROE of -1.18%. Regarding short-term risk, AIXC is less volatile compared to LFMD. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check LFMD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, AIXC is priced at $1.28, while LFLY trades at $37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas LFLY's P/E ratio is -0.04. In terms of profitability, AIXC's ROE is -1.05%, compared to LFLY's ROE of +0.17%. Regarding short-term risk, AIXC is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check LFLY's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, YI has a market cap of 55.8M. Regarding current trading prices, AIXC is priced at $1.28, while YI trades at $6.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas YI's P/E ratio is -2.27. In terms of profitability, AIXC's ROE is -1.05%, compared to YI's ROE of +0.11%. Regarding short-term risk, AIXC is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check YI's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, PETS has a market cap of 49M. Regarding current trading prices, AIXC is priced at $1.28, while PETS trades at $2.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas PETS's P/E ratio is -0.74. In terms of profitability, AIXC's ROE is -1.05%, compared to PETS's ROE of -1.22%. Regarding short-term risk, AIXC is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check PETS's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, AIXC is priced at $1.28, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas RAD's P/E ratio is -0.05. In terms of profitability, AIXC's ROE is -1.05%, compared to RAD's ROE of +2.76%. Regarding short-term risk, AIXC is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check RAD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, RNTX has a market cap of 33.9M. Regarding current trading prices, AIXC is priced at $1.28, while RNTX trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas RNTX's P/E ratio is -0.62. In terms of profitability, AIXC's ROE is -1.05%, compared to RNTX's ROE of -2.81%. Regarding short-term risk, AIXC is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check RNTX's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, KYNB has a market cap of 28.4M. Regarding current trading prices, AIXC is priced at $1.28, while KYNB trades at $7.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas KYNB's P/E ratio is -0.49. In terms of profitability, AIXC's ROE is -1.05%, compared to KYNB's ROE of -1.62%. Regarding short-term risk, AIXC is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check KYNB's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, POM has a market cap of 26.2M. Regarding current trading prices, AIXC is priced at $1.28, while POM trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas POM's P/E ratio is -4.89. In terms of profitability, AIXC's ROE is -1.05%, compared to POM's ROE of +0.07%. Regarding short-term risk, AIXC is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check POM's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, AIXC is priced at $1.28, while MEDS trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas MEDS's P/E ratio is -0.31. In terms of profitability, AIXC's ROE is -1.05%, compared to MEDS's ROE of -2.36%. Regarding short-term risk, AIXC is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check MEDS's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, AIXC is priced at $1.28, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas CJJD's P/E ratio is -0.46. In terms of profitability, AIXC's ROE is -1.05%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, AIXC is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CJJD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, NEUP has a market cap of 8.3M. Regarding current trading prices, AIXC is priced at $1.28, while NEUP trades at $4.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas NEUP's P/E ratio is -6.39. In terms of profitability, AIXC's ROE is -1.05%, compared to NEUP's ROE of -15.38%. Regarding short-term risk, AIXC is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check NEUP's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, AIXC is priced at $1.28, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas SSY's P/E ratio is -2.86. In terms of profitability, AIXC's ROE is -1.05%, compared to SSY's ROE of -0.15%. Regarding short-term risk, AIXC is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check SSY's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, MSLE has a market cap of 7.6M. Regarding current trading prices, AIXC is priced at $1.28, while MSLE trades at $5.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas MSLE's P/E ratio is -0.29. In terms of profitability, AIXC's ROE is -1.05%, compared to MSLE's ROE of -0.52%. Regarding short-term risk, AIXC is more volatile compared to MSLE. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check MSLE's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, HKPD has a market cap of 6.2M. Regarding current trading prices, AIXC is priced at $1.28, while HKPD trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas HKPD's P/E ratio is -9.48. In terms of profitability, AIXC's ROE is -1.05%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, AIXC is more volatile compared to HKPD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HKPD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, AIXC is priced at $1.28, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas MDVL's P/E ratio is -0.05. In terms of profitability, AIXC's ROE is -1.05%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, AIXC is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check MDVL's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, AIXC is priced at $1.28, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas ATNFW's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to ATNFW's ROE of -1.93%. Regarding short-term risk, AIXC is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check ATNFW's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, BGMS has a market cap of 2.2M. Regarding current trading prices, AIXC is priced at $1.28, while BGMS trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas BGMS's P/E ratio is -0.16. In terms of profitability, AIXC's ROE is -1.05%, compared to BGMS's ROE of -1.87%. Regarding short-term risk, AIXC is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check BGMS's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, NVOH has a market cap of 1.9M. Regarding current trading prices, AIXC is priced at $1.28, while NVOH trades at $20.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas NVOH's P/E ratio is 10.86. In terms of profitability, AIXC's ROE is -1.05%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, AIXC is more volatile compared to NVOH. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check NVOH's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, AIXC is priced at $1.28, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas AZNH's P/E ratio is 38.35. In terms of profitability, AIXC's ROE is -1.05%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, AIXC is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check AZNH's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, BGMSP has a market cap of 655.3K. Regarding current trading prices, AIXC is priced at $1.28, while BGMSP trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas BGMSP's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to BGMSP's ROE of -2.95%. Regarding short-term risk, AIXC is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BGMSP's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, AIXC is priced at $1.28, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, AIXC's ROE is -1.05%, compared to LFLYW's ROE of +0.17%. Regarding short-term risk, AIXC is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFLYW's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, AIXC is priced at $1.28, while BIMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas BIMI's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, AIXC is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BIMI's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, CPD has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas CPD's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to CPD's ROE of N/A. Regarding short-term risk, AIXC is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CPD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas ESRX's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, AIXC is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ESRX's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, POZN has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas POZN's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to POZN's ROE of +0.61%. Regarding short-term risk, AIXC is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check POZN's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, OREX has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas OREX's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to OREX's ROE of -0.54%. Regarding short-term risk, AIXC is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check OREX's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas SHPG's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, AIXC is more volatile compared to SHPG. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check SHPG's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.16, whereas IPXL's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -1.05%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, AIXC is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check IPXL's competition here